
INBX Stock Forecast & Price Target
INBX Analyst Ratings
Bulls say
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company that is well capitalized with $152.6 million in cash, positioning it effectively for continued development of its lead candidates, INBRX-109 and INBRX-106, which target key therapeutic areas. The anticipated readouts for these candidates in late 2025 highlight the potential for significant value generation from its proprietary protein engineering platforms. Despite a reported earnings per share of ($3.09) in the fourth quarter of 2024, the company's substantial cash reserves provide a solid foundation for future growth and strategic advancements.
Bears say
Inhibrx Biosciences has reported minimal revenues of $100K for 4Q24, which raises concerns about its ability to generate significant income amid high research and development expenses of $33.4MM and selling, general, and administrative costs of $16.7MM—both exceeding estimates. The company faces substantial risk due to a lack of differentiating clinical data, the possibility of clinical trial failures, and potential delays in drug approvals, all of which could adversely affect its stock price. Additionally, the generic nature of the clinical assets within a competitive landscape further heightens the uncertainty regarding the overall market potential of its therapeutic candidates.
This aggregate rating is based on analysts' research of Inhibrx Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
INBX Analyst Forecast & Price Prediction
Start investing in INBX
Order type
Buy in
Order amount
Est. shares
0 shares